Vienna, Austria—31 October 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held a workshop this afternoon on New Approaches to Survival Modeling in Oncology at the Society’s 19th Annual European Congress in Vienna, Austria.
The session was moderated by Andrew Briggs, DPhil, William R. Lindsay Chair of Health Economics, Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, UK. Workshop speakers included:
- Jack Ishak, PhD, Senior Research Leader, Modeling and Simulation, Evidera, Montreal, QC, Canada
- Federico Felizzi, PhD, HTA Statistician, GPMA, F. Hoffmann La Roche, Basel, Switzerland
- Aline Gauthier, MSc, Managing Director, Health Economics and Market Access, Amaris, London, UK
- Victoria Federico Paly, MHS, Senior Health Economist, ICON Health Economics and Epidemiology, New York, NY, USA
The panelists summarized the approaches of four key papers that examined various aspects of estimating or modeling overall survival effects in oncology treatment. While overall survival effects of oncology treatments are often not directly measured in clinical trials, the panelists noted that estimates of these survival effects are important for economic evaluation.
The four papers discussed in the workshop employed different methods of estimating overall survival effects in oncology treatments. The panel discussion examined the pros and cons of the approaches used in the studies, including parametric and simulation modeling tailored to mechanism of action, use of registry data for background survival estimation, adjusting for varying follow-up times and sample sizes, integrated survival modeling across treatments, and applications to cost-effectiveness and budget impact modeling.
Additional information on the ISPOR 19th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORVienna.